

SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported) JULY 9, 1997

ALEXION PHARMACEUTICALS, INC.

(Exact Name of Registrant as Specified in its Charter)

DELAWARE

0-27756

13-3648318

(State or Other Jurisdiction
of Incorporation)

(Commission
File Number)

(IRS Employer
Identification No.)

25 SCIENCE PARK, NEW HAVEN, CT

06511

(Address of Principal Executive Offices)

(Zip Code)

Registrant's telephone number, including area code: (203) 776-1790

NOT APPLICABLE

(Former Name or Former Address, if Changed Since Last Report)

ITEM 5. OTHER EVENTS

On July 9, 1997, Alexion Pharmaceuticals, Inc. issued the press release filed herewith as Exhibit 99.

ITEM 7. FINANCIAL STATEMENTS, PRO FORMA FINANCIAL INFORMATION AND EXHIBITS.

(C) EXHIBITS.

99. Press Release dated July 9, 1997.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

ALEXION PHARMACEUTICALS, INC.

Date: July 10, 1997

By: /s/ LEONARD BELL, M.D.

Name: Leonard Bell, M.D.
Title: President, Chief Executive
Officer, Secretary and Treasurer

IMMEDIATE RELEASE

Contact:	Leonard Bell, M.D. President and CEO Alexion Pharmaceuticals 203/776-1790	Kate de Santis (Investor) Susan Farley (Media) Dewe Rogerson Inc. 212/688-6840
----------	--	---

ALEXION RECEIVES \$11.2 MILLION IN PRIVATE PLACEMENT

New Haven, CT, July 9, 1997 -- Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) today announced that it has received from institutional investors \$11.2 million from the private placement of stock announced last month. Robertson, Stephens & Company LLC served as Placement Agent in the transaction.

"We believe that these proceeds will allow us to importantly augment the clinical development of our lead C5 complement inhibitors and more broadly advance the manufacturing, preclinical development and clinical development of our portfolio product candidates," said Dr. Leonard Bell, President and Chief Executive Officer of Alexion.

Proceeds from the private placement will be used to fund the Company's research and development activities including ongoing and planned clinical studies, production of clinical trial material, preclinical studies, and for general corporate purposes.

Alexion Pharmaceuticals, Inc. was founded in 1992 and is engaged in the development of selective immunotherapeutic drugs that generally are designed to inhibit the disease-causing segments of the immune system while preserving the disease-preventing aspects of the immune system. The Company is developing three technology platforms: C5 Complement Inhibitors and Apogen T-Cell Therapeutics which together target severe cardiovascular and autoimmune disorders; and xenografts for organ transplants.

This news release contains forward looking statements. Such statements are subject to certain factors which may cause the Alexion's plans to differ or results to vary from those expected including unexpected preclinical or clinical results, the need for additional research and testing, delays in manufacturing, access to capital and funding, delays in development of commercial relationships and a variety of risks set forth from time to time in the Alexion's filings with the Securities and Exchange Commission, including but not limited to Alexion's Annual Report on Form 10-K for the year ended July 31, 1996 and those risks as discussed in Alexion's Registration Statement (Registration No. 333-29617). Alexion undertakes no obligation to publicly release results of any of these forward-looking statements which may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. At the time of sale to investors, the shares of Common Stock had not been registered under the Securities Act of 1933, as amended, and may not be offered and

sold in the United States absent registration under such Act or an applicable exemption from registration. Subsequent to the sale, a registration statement relating to the resale of the shares was declared effective by the Securities and Exchange Commission. This press release shall not constitute an offer to sell or the solicitation of an offer to buy the Common Stock nor shall there be any sale of these securities in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state.